Abstract: The present invention is the creation of stable boron isotope (10B) containing nanosilica particles composing of amino acids, amino-oligosaccharides, and oligopeptides appropriate to the improvement of drug delivery system (DDS) function of delivering more boron to tumors selectively to facilitate the efficacy of boron neutron capture therapy (BNCT).

Abstract: Provided is a new boron isotope (10B) tracing drug which can exhibit wide-area molecular-targeting function and stereotactic destructive power. The invented boron isotope (10B) tracing drug has higher selective tumor-targeting and tumor-accumulating pharmacokinetic functions appropriate for neutron beam dynamic therapy (NBDT) and boron neutron capture therapy (BNCT).

Abstract: An object of the present invention is to provide a method of preparing an enzyme-treated bovine colostrum, comprising a step of bringing a bovine colostrum into contact with ?-galactosidase, and a pharmaceutical composition comprising the enzyme-treated bovine colostrum. The enzyme-treated bovine colostrum is useful for treatment, prevention, amelioration and maintenance of remission of diseases such as a cancer and an infectious disease.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: An object of the present invention is to provide a method of preparing an enzyme-treated bovine colostrum, comprising a step of bringing a bovine colostrum into contact with ?-galactosidase, and a pharmaceutical composition comprising the enzyme-treated bovine colostrum. The enzyme-treated bovine colostrum is useful for treatment, prevention, amelioration and maintenance of remission of diseases such as a cancer and an infectious disease.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with ?-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.

Abstract: In a method of producing an oil-in-water type emulsion containing an internally crosslinked fine resin particle, the fine resin particle is encapsulated in an emulsion particle having an average particle diameter of 0.02 to 0.3 ?m. The method includes a step of undergoing phase transition from a water-in-oil type emulsion (Y) which includes a resin (A) having a cationic group or an anionic group, an acid or a base (B) neutralizing 20 to 150 mole percent of the cationic group or the anionic group in the resin (A), an internally crosslinked fine resin particle (C), having an average particle diameter of 0.01 to 0.2 ?m, dispersed in an oil phase and an aqueous medium (D) to an oil-in-water type emulsion (Z) by adding the aqueous medium (D) further to the water-in-oil type emulsion (Y).

Abstract: In a method of producing an oil-in-water type emulsion containing an internally crosslinked fine resin particle, the fine resin particle is encapsulated in an emulsion particle having an average particle diameter of 0.02 to 0.3 &mgr;m. The method includes a step of undergoing phase transition from a water-in-oil type emulsion (Y) which includes a resin (A) having a cationic group or an anionic group, an acid or a base (B) neutralizing 20 to 150 mole percent of the cationic group or the anionic group in the resin (A), an internally crosslinked fine resin particle (C), having an average particle diameter of 0.01 to 0.2 &mgr;m, dispersed in an oil phase and an aqueous medium (D) to an oil-in-water type emulsion (Z) by adding the aqueous medium (D) further to the water-in-oil type emulsion (Y).

Abstract: The present invention provides an improved 2 wet coating system. The present invention relates to a process for forming a multi layered coated film comprising the steps of: forming an uncured electrodeposition coated film on an electrically conductive substrate, applying an intermediate coating on the electrodeposition coated film, and then simultaneously heating and curing the uncured electrodeposition coated film and an uncured intermediate coated film, forming an uncured base coated film on the intermediate coated film, applying a clear top coating on the base coated film, and then simultaneously heating and curing the uncured base coated film and an uncured clear coated film; wherein the electrodeposition coating forms a self-stratifying coated film, and a dynamic glass transition temperature of a resin layer (&agr;) in direct contact with the electrically conductive substrate and that of a resin layer (&bgr;) in direct contact with the intermediate coated film are controlled.

Abstract: Disclosed are an efficient, safe process for producing artepillin C and derivatives thereof by an organic synthesis. The process comprises a step of reacting a phenol derivative with an acrylate or acrylic acid.

Abstract: A process for cationic electrodeposition coating which comprises the steps of: (1) immersing a substrate in a cationic electrodeposition coating composition: (2) applying a voltage between an anode and said substrate, which serves as a cathode, to thereby cause coat film deposition; and (3) further applying a voltage to the coat film deposited so as to increase electric resistance per unit volume of said coat film, wherein, in said step (3), coat films are deposited at those sites of the substrate where coat films have not yet been deposited, said cationic electrodeposition coating composition having a time point when the electric resistance per unit volume of the coat film deposited increases in the course of electrodeposition under constant-current conditions.

Abstract: A method of stabilization of electrolyte bath in electrocoating by immersing a substrate in the bath filled with a cationic electrocoating composition containing a basic resin and an amine compound and carrying out electrocoating; wherein said basic resin in said bath contains, per 100 grams of the resin solids, 10 to 300 millimoles of sulfonium group and 50 to 2,000 millimoles of carbon—carbon unsaturated bond, and said amine compound is contained in an amount of 1 to 50 millimoles per 100 grams of the basic resin solids in the bath, said amount being not less than 5 mole percent relative to the sulfonium group content in said basic resin, so that the sulfonium group remaining in the coat amount to not more than 50% relative to the sulfonium group contained in the electrocoating composition in said bath.

Abstract: A cation electrodeposition coating process and cation electrodeposition coating composition that have a sufficient throwing power are provided. A process for cationic electrodeposition coating which comprises the steps of:(1) immersing a substrate in a cationic electrodeposition coating composition;(2) applying a voltage between an anode and the substrate, which serves as a cathode, to thereby cause coat film deposition; and(3) further applying a voltage to the coat film deposited so as to increase electric resistance per unit volume of the coat film,wherein, in step (3), coat films are deposited at those sites of the substrate where coat films have not yet been deposited, the cationic electrodeposition coating composition having a time point when the electric resistance per unit volume of the coat film deposited increases in the course of electrodeposition under constant-current conditions.

Abstract: The invention provides a film composition comprising a thermoplastic polymer having a melt flow rate of 20 to 2000 (g/10 min), and a flame-retardant, and a self-extinguishing laminated film comprising at least two thermoplastic polymer films, at least one of the thermoplastic polymer films being a meltable film prepared from the composition.

Abstract: A character recognition method includes steps of comparing input image data with character patterns of a predetermined dictionary and recognizing a character indicated by the input image data without requiring any special hardware in a conventional character recognition apparatus. Namely, the input image data is processed by using an unwanted-dot elimination mask and processed by using a positive mask and negative mask of each of the character patterns in the dictionary, and then a discrepancy ratio of each of the character patterns is calculated. Consequently, highly accurate character recognition can be carried out at a low cost without using special hardware, by decreasing the negative infludence of a flaw, a missing portion, dust, and the like.

Abstract: A photocurable resin composition comprising(A) a copolymer composed of, as structural units,(a) 20 to 70% by weight of a hydroxyl group-containing acrylic monomer unit represented by the following formula ##STR1## wherein R.sub.1 and R.sub.2, independently from each other, represent a hydrogen atom, a methyl group or an ethyl group and n is 1, 2 or 3, and(b) 5 to 80% by weight of a nitrogen-containing acrylic monomer unit represented by the following formula ##STR2## wherein R.sub.3 represents a hydrogen atom or a methyl group, X represents 0 or NH, R.sub.4 represents a linear or branched alkylene group having 2 or 3 carbon atoms, R.sub.5, R.sub.6 and R.sub.7, independently from each other, represent a hydrogen atom or a linear or branched alkyl group having 1 to 4 carbon atoms and Y.sup..crclbar. represents an anion of an acid, and(B) a diazo compound or an azide compound.